Some studies have reported increased densities of CD8+ T-cell infiltrates in serial tumor biopsies of patients with metastatic melanoma who received ipilimumab and pembrolizumab and exhibited a positive response to the therapy [82,83]. This evidence concerns the gene CD8A and metastatic melanoma.